Novartis' phase III PREVENT trial of Cosentyx in patients with nr-axSpA meets primary endpoint: Basel Wednesday, November 13, 2019, 09:00 Hrs [IST] Novartis, a leader in rheumatol ...

Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...

Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months ...

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

(RTTNews) - Novartis (NVS,NOVN.SW) announced that its interleukin-17A inhibitor Cosentyx (secukinumab) met the primary and all secondary endpoints in the Phase III REPLENISH trial. The study evaluated ...

Novartis said it is launching a direct-to-patient platform in the U.S. to sell a discounted version of its Cosentyx drug, the latest big pharma company to move to cut prices ahead of the Trump ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

The 2025 European Academy of Dermatology and Venereology (2025 EADV), the largest dermatology conference in Europe, opened on the 17th (local time) in Paris, France. Running through the 20th, EADV ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 18, 2025 /EINPresswire / -- How Much Is the Cosentyx Drug Market Growing? The global Cosentyx drug market is set for significant expansion, with long-term ...